In conclusion, our present results, for the first time, demonstrate that LBP ameliorates HFD-induced fatty liver in vivo and in vitro, in which modulation of the hepatic AMPK/SREBP-1c pathway plays a pivotal role. The gene discussed is SREBF1; the disease is fatty liver disease.